Preemptive Pharmacogenomics
Preemptive Pharmacogenomics is a pharmacogenomic strategy that involves the prospective genotyping of individuals for drug response-related genetic variants prior to the onset of therapy, in order to guide future medication selection and dosing.
16
Publications
1.9K
Citations
346
Authors
88
Institutions
Publications per year
2017–2026
4
Parents
16
Suzette J. Bielinski, Janet E. Olson, Jyotishman Pathak et al. · Mayo Clinic Proceedings · 2014 · 304 citations · Full text
Cathelijne H. van der Wouden, Anne Cambon‐Thomsen, Erika Cecchin et al. · Clinical Pharmacology & Therapeutics · 2016 · 292 citations · Full text
Laura J. Rasmussen‐Torvik, Sarah Stallings, Allan Gordon et al. · Clinical Pharmacology & Therapeutics · 2014 · 244 citations · Full text
Preemptive Pharmacogenomic Testing for Precision Medicine
Yuan Ji, Jennifer M. Skierka, Joseph H. Blommel et al. · Journal of Molecular Diagnostics · 2016 · 196 citations · Full text
1–5 of 16
346
4
h-index
3
h-index
3
h-index
3
h-index
3
h-index
1–5 of 346
88
Mayo Clinic
Rochester, United States
5 h-index
52 publications
8.2K citations
Mayo Clinic in Florida
Jacksonville, United States
5 h-index
50 publications
7.8K citations
Golden Helix Foundation
London, United Kingdom
3 h-index
5 publications
503 citations
Center for Human Genetics
Bar Harbor, United States
3 h-index
5 publications
968 citations
University of Patras
Pátrai, Greece
3 h-index
11 publications
839 citations
Mayo Clinic in Arizona
Scottsdale, United States
3 h-index
73 publications
9.1K citations
WinnMed
Decorah, United States
3 h-index
10 publications
1.3K citations

Uppsala University
Uppsala, Sweden
2 h-index
3 publications
627 citations
1–8 of 88
CPT · 5 publications · 786 citations
5
h-index
1 publications · 45 citations
1
h-index
1 publications · 36 citations
1
h-index
1 publications · 43 citations
1
h-index
1 publications · 64 citations
1
h-index
1–5